Submitted by Anonymous (not verified) on 6 March 2026 - 12:50
Human medicines European public assessment report (EPAR): Tyruko, natalizumab, Date of authorisation: 22/09/2023, Revision: 3, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Tyruko, natalizumab, Date of authorisation: 22/09/2023, Revision: 3, Status: Authorised